MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
NCT02364713 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17
Last updated 2025-12-11
Summary
This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
Conditions
- Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Ovarian Carcinosarcoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Primary Peritoneal Carcinosarcoma
- Primary Peritoneal Clear Cell Adenocarcinoma
- Primary Peritoneal Endometrioid Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Primary Peritoneal Transitional Cell Carcinoma
- Primary Peritoneal Undifferentiated Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
Interventions
- BIOLOGICAL
-
Given IV
- DRUG
-
Gemcitabine Hydrochloride
Given IV
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- BIOLOGICAL
-
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Given IP
- DRUG
-
Given IV
- DRUG
-
Pegylated Liposomal Doxorubicin Hydrochloride
Given IV
- OTHER
-
Quality-of-Life Assessment
Ancillary studies
- DRUG
-
Topotecan Hydrochloride
Given IV
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Evanthia Galanis, M.D. · Mayo Clinic in Rochester
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-03-13
- Primary Completion
- 2022-01-13
- Completion
- 2022-01-13
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00096993 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
NCT02606305 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT06483048 ·Status: RECRUITING ·Phase: PHASE1
-
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03552471 ·Status: COMPLETED ·Phase: PHASE1
-
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
NCT03704467 ·Status: COMPLETED ·Phase: PHASE1
-
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
NCT01010126 ·Status: COMPLETED ·Phase: PHASE2
-
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
NCT04274426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
NCT06083844 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318 ·Status: COMPLETED ·Phase: PHASE2
-
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02833506 ·Status: WITHDRAWN ·Phase: PHASE1
-
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT01536054 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT05920798 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855 ·Status: COMPLETED ·Phase: PHASE3
-
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
NCT03608618 ·Status: TERMINATED ·Phase: PHASE1
-
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT02046421 ·Status: COMPLETED ·Phase: PHASE1
-
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
NCT00023634 ·Status: TERMINATED ·Phase: PHASE1
-
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
NCT05243524 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00006041 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT04092270 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01673217 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT04606914 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
NCT03367871 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
NCT00047632 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
NCT02146313 ·Status: COMPLETED ·Phase: PHASE1
-
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3